While the important contributions of PI3K/AKT activation for medulloblastoma development suggest that PI3K inhibitors might show promise for the treatment of this tumour, the narrow therapeutic window of pan-PI3K inhibitors has been discouraging27. The gene discussed is AKT1; the disease is medulloblastoma.